Psychological Therapies in Patients with Irritable Bowel Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2015 Mar 25

PMID 25802514

Citations 14

Authors

Osama Altayar

Varun Sharma

Larry J Prokop

Amit Sood

Mohammad Hassan Murad

Affiliations

Soon will be listed here.

Abstract

Background. Irritable bowel syndrome (IBS) is a poorly understood disease with few effective treatments. Psychosocial factors are believed to contribute to the pathogenesis of IBS. Objective. To evaluate the evidence for psychological therapies in IBS treatment. Methods. We searched six medical databases through February 6, 2014, for randomized controlled trials (RCTs) of psychological therapies for the treatment of IBS. Two independent reviewers identified the RCTs, extracted the data, and assessed trial quality. We used the random-effect model to pool standardized mean difference (SMD) and 95% confidence interval (CI) across trials. Results. 15 RCTs that mostly evaluated cognitive behavioral therapy were included. Psychological therapies were associated with improvement in IBS symptoms severity scales (SMD -0.618; 95% CI: -0.853 to -0.383), IBS-Quality of Life (SMD 0.604; 95% CI: 0.440 to 0.768), and abdominal pain (SMD -0.282; 95% CI: -0.562 to -0.001). No statistically significant effect was observed on diarrhea or constipation. Limitations. The trials were at increased risk of bias and the overall sample size was small leading to imprecision. Conclusion. Psychological therapies may improve the quality of life and symptom severity in IBS. The effect size noted is moderate to large and is clinically meaningful.

Citing Articles

Biobehavioral approach to distinguishing panic symptoms from medical illness.

Tunnell N, Corner S, Roque A, Kroll J, Ritz T, Meuret A Front Psychiatry. 2024; 15:1296569.

PMID: 38779550 PMC: 11109415. DOI: 10.3389/fpsyt.2024.1296569.

Formative Evaluation of a Comprehensive Self-Management Intervention for Irritable Bowel Syndrome, Comorbid Anxiety, and Depression: Mixed Methods Study.

Kamp K, Yang P, Friedman E, Lopez A, Iribarren S, Barney P JMIR Form Res. 2024; 8:e43286.

PMID: 38294871 PMC: 10867748. DOI: 10.2196/43286.

Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update.

Andrews C, Bradette M J Can Assoc Gastroenterol. 2020; 3(6):e37-e48.

PMID: 33241185 PMC: 7678738. DOI: 10.1093/jcag/gwz034.

Proceedings of the 2018 Advances In Motility and In NeuroGastroenterology: AIMING for the Future Single Topic Symposium.

Ambartsumyan L, Khlevner J, Nurko S, Rosen R, Kaul A, Pandolfino J J Pediatr Gastroenterol Nutr. 2020; 71(2):e59-e67.

PMID: 32287151 PMC: 8451965. DOI: 10.1097/MPG.0000000000002720.

Persistent physical symptoms reduction intervention: a system change and evaluation in secondary care (PRINCE secondary) - a CBT-based transdiagnostic approach: study protocol for a randomised controlled trial.

Chalder T, Patel M, James K, Hotopf M, Frank P, Watts K BMC Psychiatry. 2019; 19(1):307.

PMID: 31640632 PMC: 6805658. DOI: 10.1186/s12888-019-2297-y.

References

Gholamrezaei A, Khanpour Ardestani S, Emami M . Where does hypnotherapy stand in the management of irritable bowel syndrome? A systematic review. J Altern Complement Med. 2006; 12(6):517-27. DOI: 10.1089/acm.2006.12.517. View

Kennedy T, Chalder T, McCrone P, Darnley S, Knapp M, Jones R . Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technol Assess. 2006; 10(19):iii-iv, ix-x, 1-67. DOI: 10.3310/hta10190. View

Eypasch E, Williams J, Wood-Dauphinee S, Ure B, Schmulling C, Neugebauer E . Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg. 1995; 82(2):216-22. DOI: 10.1002/bjs.1800820229. View

Lackner J, Jaccard J, Krasner S, Katz L, Gudleski G, Holroyd K . Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol. 2008; 6(8):899-906. PMC: 2630498. DOI: 10.1016/j.cgh.2008.03.004. View

Blanchard E, Lackner J, Sanders K, Krasner S, Keefer L, Payne A . A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther. 2006; 45(4):633-48. DOI: 10.1016/j.brat.2006.07.003. View

Manning A, Thompson W, Heaton K, Morris A . Towards positive diagnosis of the irritable bowel. Br Med J. 1978; 2(6138):653-4. PMC: 1607467. DOI: 10.1136/bmj.2.6138.653. View

Lackner J, Gudleski G, Keefer L, Krasner S, Powell C, Katz L . Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2010; 8(5):426-32. PMC: 3144205. DOI: 10.1016/j.cgh.2010.02.007. View

Francis C, Morris J, Whorwell P . The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997; 11(2):395-402. DOI: 10.1046/j.1365-2036.1997.142318000.x. View

Labus J, Gupta A, Gill H, Posserud I, Mayer M, Raeen H . Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention. Aliment Pharmacol Ther. 2012; 37(3):304-15. PMC: 3829380. DOI: 10.1111/apt.12171. View

10.

Kennedy T, Jones R, Darnley S, Seed P, Wessely S, Chalder T . Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ. 2005; 331(7514):435. PMC: 1188111. DOI: 10.1136/bmj.38545.505764.06. View

11.

Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N . The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003; 124(2):303-17. DOI: 10.1053/gast.2003.50055. View

12.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

13.

Mundt J, Marks I, Shear M, Greist J . The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002; 180:461-4. DOI: 10.1192/bjp.180.5.461. View

14.

Ioannidis J, Trikalinos T . The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007; 176(8):1091-6. PMC: 1839799. DOI: 10.1503/cmaj.060410. View

15.

FitzGerald L, Kehoe P, Sinha K . Hypothalamic--pituitary-- adrenal axis dysregulation in women with irritable bowel syndrome in response to acute physical stress. West J Nurs Res. 2009; 31(7):818-36. DOI: 10.1177/0193945909339320. View

16.

Patrick D, Drossman D, Frederick I, DiCesare J, Puder K . Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998; 43(2):400-11. DOI: 10.1023/a:1018831127942. View

17.

Thompson W, Longstreth G, Drossman D, Heaton K, Irvine E, Muller-Lissner S . Functional bowel disorders and functional abdominal pain. Gut. 1999; 45 Suppl 2:II43-7. PMC: 1766683. DOI: 10.1136/gut.45.2008.ii43. View

18.

Wilson S, Maddison T, Roberts L, Greenfield S, Singh S . Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther. 2006; 24(5):769-80. DOI: 10.1111/j.1365-2036.2006.03028.x. View

19.

McCrone P, Knapp M, Kennedy T, Seed P, Jones R, Darnley S . Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2008; 20(4):255-63. DOI: 10.1097/MEG.0b013e3282f2519d. View

20.

Bohmelt A, Nater U, Franke S, Hellhammer D, Ehlert U . Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls. Psychosom Med. 2005; 67(2):288-94. DOI: 10.1097/01.psy.0000157064.72831.ba. View